[go: up one dir, main page]

MX2009012383A - Derivados de arilamida pirimidona para el tratamiento de enfermedades neurodegenerativas. - Google Patents

Derivados de arilamida pirimidona para el tratamiento de enfermedades neurodegenerativas.

Info

Publication number
MX2009012383A
MX2009012383A MX2009012383A MX2009012383A MX2009012383A MX 2009012383 A MX2009012383 A MX 2009012383A MX 2009012383 A MX2009012383 A MX 2009012383A MX 2009012383 A MX2009012383 A MX 2009012383A MX 2009012383 A MX2009012383 A MX 2009012383A
Authority
MX
Mexico
Prior art keywords
group
alkyl group
atom
hydrogen atom
optionally substituted
Prior art date
Application number
MX2009012383A
Other languages
English (en)
Inventor
Alistair Lochead
Mourad Saady
Philippe Yaiche
Corinne Veronique
Nathalie Chereze
Thierry Gallet
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MX2009012383A publication Critical patent/MX2009012383A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • C07D239/36One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un derivado de pirimidona representado por la fórmula (I) o una de sus sales o uno de sus solvatos o uno de sus hidratos, en la que: X representa dos átomos de hidrógeno, un átomo de azufre, un átomo de oxígeno o un grupo alquilo C1-2 y un átomo de hidrógeno; Z representa un enlace, un átomo de oxígeno, un átomo de nitrógeno sustituido con un átomo de hidrógeno o un grupo alquilo C1-3, un átomo de azufre, un grupo metileno opcionalmente sustituido con uno o dos grupos elegidos entre un grupo alquilo C1-6, un grupo hidroxilo, un grupo alcoxi C1-6, un grupo alquilo C1-2 perhalogenado o un grupo amino; R1 representa un anillo de 2, 4 ó 5-pirimidina o un anillo de 4-piridina, estando el anillo opcionalmente sustituido con un grupo alquilo C1-6, un grupo alcoxi C1-6 o un átomo de halógeno; R2 representa un anillo de benceno, un anillo de naftaleno o un grupo bencilo; estando los anillos opcionalmente sustituidos con 1 a 4 sustituyentes elegidos entre un grupo alquilo C1-6, un grupo cicloalquilo C3-7, un grupo cicloalquil C3-7-alquilo- C1-6, un átomo de halógeno, un grupo alquilo C1-2 perhalogenado, un grupo alquilo C1-3 halogenado, un grupo hidroxilo, un grupo heteroarilo opcionalmente sustituido con un grupo alquilo C1-6, un grupo cicloalquilo C3-7, un grupo cicloalquil C3-7-alquilo-C1-6, un grupo alcoxi C1-6 opcionalmente sustituido con un grupo cicloalquilo C3-7, un grupo alcoxi C1-2 perhalogenado, un grupo alquil C1-6-sulfonilo, un grupo nitro, ciano, amino, monoalquil C1-6-amino o un grupo dialquil C2-12-amino, un grupo acetoxi o un grupo aminosulfonilo; R3 representa un átomo de hidrógeno, un grupo alquilo C1-6 o un átomo de halógeno; R4 representa un átomo de hidrógeno o un grupo alquilo C1-6; R5 representa un átomo de hidrógeno o un grupo alquilo C1-6; R6 representa un átomo de hidrógeno o un grupo alquilo C1-6 R7 representa un átomo de hidrógeno o un grupo alquilo C1-6; n representa de 0 a 3; y m representa 0, en forma de una base libre o de una sal de adición con un ácido.
MX2009012383A 2007-05-16 2008-05-14 Derivados de arilamida pirimidona para el tratamiento de enfermedades neurodegenerativas. MX2009012383A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07290625A EP1992620A1 (en) 2007-05-16 2007-05-16 Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases
PCT/IB2008/002446 WO2008155669A2 (en) 2007-05-16 2008-05-14 Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
MX2009012383A true MX2009012383A (es) 2009-12-03

Family

ID=38610549

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012383A MX2009012383A (es) 2007-05-16 2008-05-14 Derivados de arilamida pirimidona para el tratamiento de enfermedades neurodegenerativas.

Country Status (15)

Country Link
US (1) US8592436B2 (es)
EP (2) EP1992620A1 (es)
JP (1) JP5509070B2 (es)
KR (1) KR20100016528A (es)
CN (1) CN101679305A (es)
AR (1) AR066603A1 (es)
AU (1) AU2008264901A1 (es)
BR (1) BRPI0811527A2 (es)
CA (1) CA2687258A1 (es)
EA (1) EA200971062A1 (es)
IL (1) IL201562A0 (es)
MX (1) MX2009012383A (es)
NZ (1) NZ581163A (es)
TW (1) TW200904436A (es)
WO (1) WO2008155669A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010104818A1 (en) * 2009-03-09 2010-09-16 Bristol-Myers Squibb Company Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2015155738A2 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4145423A (en) 1976-02-10 1979-03-20 Rhone-Poulenc Industries Pyrimidinyl-1,2-dithiole compounds and anti-bilharzia compositions thereof
US5629322A (en) 1994-11-15 1997-05-13 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase
KR100581199B1 (ko) * 1998-06-19 2006-05-17 카이론 코포레이션 글리코겐 신타제 키나제 3의 억제제
GB9820658D0 (en) 1998-09-22 1998-11-18 Medical Res Council Treatment of infection
CA2457952C (en) 2001-09-21 2009-11-10 Sanofi-Synthelabo Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h) one derivatives for neurodegenerative disorders
CA2510170C (en) 2002-12-16 2011-05-24 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
EP1454909B1 (en) * 2003-03-07 2008-08-20 Sanofi Aventis 8'-pyridinyl-dihydrospiro- (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one derivatives and their use against neurodegenerative diseases
AR043486A1 (es) 2003-03-07 2005-08-03 Sanofi Aventis Derivados de 2-(diaza-biciclo-alquil)-pirimidona
EP1790649A1 (en) * 2005-11-21 2007-05-30 Sanofi-Aventis Substituted bicyclic pyrimidone derivatives

Also Published As

Publication number Publication date
WO2008155669A2 (en) 2008-12-24
EA200971062A1 (ru) 2010-06-30
NZ581163A (en) 2011-09-30
JP2010526866A (ja) 2010-08-05
EP1992620A1 (en) 2008-11-19
US20100087460A1 (en) 2010-04-08
KR20100016528A (ko) 2010-02-12
BRPI0811527A2 (pt) 2014-11-18
TW200904436A (en) 2009-02-01
IL201562A0 (en) 2010-05-31
US8592436B2 (en) 2013-11-26
CA2687258A1 (en) 2008-12-24
CN101679305A (zh) 2010-03-24
EP2148866A2 (en) 2010-02-03
EP2148866B1 (en) 2013-07-17
AR066603A1 (es) 2009-09-02
JP5509070B2 (ja) 2014-06-04
AU2008264901A1 (en) 2008-12-24
WO2008155669A3 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
MX2010008361A (es) Derivados de arilamida oxazepinopirimidona sustituidos.
MX2009012383A (es) Derivados de arilamida pirimidona para el tratamiento de enfermedades neurodegenerativas.
MX2009012377A (es) Compuestos de arilamida pirimidona.
MX2010008363A (es) Derivados de arilamida diazepinopirimidona sustituidos para el tratamiento de enfermedades neurodegenerativas causadas por la actividad anormal de gsk3-beta.
MX2009012380A (es) Compuestos de heteroarilamida pirimidona.
MX2010008362A (es) Derivados de heteroarilamida diazepinopirimidona sustituidos.
MX2010008360A (es) Derivados de oxazepinopirimidona heteroarilamida sustituidos.
EA201170099A1 (ru) Замещенные пиримидин-4-оновые производные
EA200970598A1 (ru) Замещенные производные гетероарилпиридопиримидона
EA200800815A1 (ru) 2-анилин-4-арилзамещенные тиазольные производные
EA201170098A1 (ru) Замещенные производные алкилпиримидин-4-она
MY177250A (en) Novel nicotinamide derivative or salt thereof
NO20092770L (no) Nye aminopyrimidinderivater som PLK1-inhibitorer
CY1109890T1 (el) ΠΑΡΑΓΩΓΑ 8-ΥΠΟΚΑΤΕΣΤΗΜΕΝΗΣ-6,7,8,9- ΤΕΤΡΑΫΔΡΟΠΥΡΙΜΙΔΟ[1,2-α] ΠΥΡΙΜΙΔΙΝ-4-ΟΝΗΣ
EA201170093A1 (ru) Замещенные n-оксидпиразиновые производные
MY169179A (en) Novel piperidine compound or salt thereof
EA200971060A1 (ru) Гетероариламидные пиримидоновые производные
AR063577A1 (es) Derivados 8- piperidinil - pirimido [1 2 a] pirimidin -6-ona y 8- piperidinil-2- pirimidinil- pirimido [1,2-a] pirimidin -6- ona sustituidos
EA201071259A1 (ru) Спиро(пиперидин-4,2-пирролидин)-1-(3,5-трифторметилфенил)метилкарбоксамиды в качестве антагонистов рецептора nk1 тахикинина
TH106958A (th) สารประกอบเอริลเอไมด์ ไพริมิโดน
TH104960A (th) อนุพันธ์ซับสทิทิวเต็ดอะริลลาไมด์ออกซาเซพิโนไพริมิโดน
ATE500243T1 (de) Carbonsäureamidverbindung und deren verwendung
MX2007005892A (es) Derivados de acido piridonacarboxilico novedosos y sales de los mismos.
TW200942538A (en) 2-benzoylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof
ATE488512T1 (de) Piperazinderivate als ccr3-hemmer

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal